<?xml version='1.0' encoding='utf-8'?>
<document id="26459026"><sentence text="Identifying high risk medications causing potential drug-drug interactions in outpatients: A prescription database study based on an online surveillance system." /><sentence text="Drug-drug interactions (DDIs) are a significant cause for adverse drug events (ADEs)" /><sentence text=" DDIs are often predictable and preventable, but their prevention and management require systematic service development" /><sentence text=" Most DDI studies focus on interaction rates in hospitalized patients" /><sentence text=" Less is known of DDIs in outpatients, particularly how community pharmacists could contribute to DDI management by applying their surveillance systems for identifying high-risk medications" /><sentence text="" /><sentence text="The study was related to the implementation of the first online DDI surveillance system in Finnish community pharmacies" /><sentence text=" The goal was to demonstrate how community pharmacies can utilize their prospective surveillance system 1) for identifying high risk medications causing potential DDIs in outpatients, 2) for collaborative service development with local physicians, and 3) for academic risk management research purposes" /><sentence text="" /><sentence text="All DDI alerts given by the online surveillance system were collected during a one-month period in 16 out of 17 University Pharmacy outlets in Finland, covering approximately 10% of the national outpatient prescription volume" /><sentence text=" The surveillance system was based on the FASS database, which categorizes DDIs into four classes (A-D) according to their clinical significance" /><sentence text="" /><sentence text="Potential drug-drug DDIs were analyzed for 276,891 dispensed community pharmacy prescriptions" /><sentence text=" Potential DDIs were associated with 10" /><sentence text="8%, or 31,110 of these prescriptions" /><sentence text=" Clinically significant interaction alerts categorized as FASS classes D (most severe, should be avoided) and C (clinically significant but controllable) were associated with 0" /><sentence text="5% and 7" /><sentence text="0% of the prescriptions, respectively" /><sentence text=" Methotrexate and warfarin had the highest risk of causing potentially serious (class D) interactions"><entity charOffset="1-13" id="DDI-PubMed.26459026.s19.e0" text="Methotrexate" /><entity charOffset="18-26" id="DDI-PubMed.26459026.s19.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.26459026.s19.e0" e2="DDI-PubMed.26459026.s19.e0" /><pair ddi="false" e1="DDI-PubMed.26459026.s19.e0" e2="DDI-PubMed.26459026.s19.e1" /></sentence><sentence text=" These interaction alerts were most frequently between methotrexate and NSAIDs and warfarin and NSAIDs"><entity charOffset="55-67" id="DDI-PubMed.26459026.s20.e0" text="methotrexate" /></sentence><sentence text=" In general, NSAIDs were the most commonly interacting drugs in this study" /><sentence text="" /><sentence text="This study demonstrates that community pharmacies can actively contribute to DDI risk management and systematically use their surveillance systems for identifying patients having clinically significant DDIs" /><sentence text=" The findings also indicate that the majority of potentially serious interactions in outpatients involve a limited number of drugs, particularly NSAIDs, warfarin and methotrexate"><entity charOffset="166-178" id="DDI-PubMed.26459026.s24.e0" text="methotrexate" /></sentence><sentence text=" Further research should focus on community pharmacists' involvement in DDI risk management in collaboration with local health care providers" /><sentence text="" /></document>